An ascending multiple dose study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SAM-531 administered orally to healthy Japanese young male and elderly subjects

Trial Profile

An ascending multiple dose study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SAM-531 administered orally to healthy Japanese young male and elderly subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs Cerlapirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 05 Feb 2008 Status changed from recruiting to completed. Updated from ClinicalTrials.gov.
    • 24 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top